Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) – of which the University of Oxford is a lead partner – announced today the start of vaccinations in a Phase I clinical trial of a novel HIV vaccine candidate.

HIV virus

With the first dose given at the Center for Family Health Research in Zambia (CFHRZ), in Lusaka, Zambia, the trial will extend to sites in Kenya and Uganda in the coming weeks.

Dr. William Kilembe, project director of CFHRZ and trial principal investigator, said: ‘International partnerships are crucial in developing and evaluating HIV vaccine candidates in countries and communities where HIV vaccines will ultimately have the greatest public health impact.

‘CFHRZ is proud to be part of the consortium evaluating HIVconsvX and to deliver the first dose of this experimental HIV vaccine in the HIV-CORE 006 trial.’

The goal of the trial, known as HIV-CORE 006, is to evaluate the safety, tolerability, and immunogenicity of a novel vaccine candidate, HIVconsvX, a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

Professor Tomas Hanke, Professor of Vaccine Immunology at the Nuffield Department of Medicine, and lead researcher on the trial, said: ‘This highly rational, bioinformatics-assisted, vaccine design addresses the enormous variability of HIV-1 - one of the greatest challenges to the development of an effective vaccine against HIV/AIDS.’

Dr. Paola Cicconi, Senior Clinical Research Fellow at the University of Oxford, and the trial Chief Investigator, said: ‘An effective HIV vaccine remains an essential but unrealised component of the HIV prevention toolkit and remains the most cost-effective and desirable solution to end the HIV epidemic.’

The trial will see 88 healthy, HIV-negative adults, aged 18-55, who are considered not to be at high risk of infection, receive one dose of the vaccine initially, followed by a further booster dose at four weeks.

While most HIV vaccine candidates work by inducing antibodies generated by B-cells, HIVconsvX induces the immune system’s potent, pathogen obliterating T cells, targeting them to highly conserved and therefore vulnerable regions of HIV – an “Achilles heel” common to most HIV variants.

Dr. Vincent Muturi-Kioi, medical director at IAVI, said: ‘It is crucial that we have a diverse pipeline of HIV vaccine candidates that target both the antibody and T-cell arms of the immune system.

‘HIVconsvX represents an exciting new hypothesis in engaging the killer T-cell arm to prevent HIV infection.’

At present, prevention of HIV largely focuses on behavioral and biomedical interventions such as voluntary medical male circumcision, condom use, and anti-retroviral drugs used prior to exposure.

Dr. Walter Jaoko, director of KAVI-Institute of Clinical Research (KAVI-ICR) and trial principal investigator, said: ‘Preventive vaccines, especially those that provide durable protection against all major HIV subtypes, would be a powerful tool for people not able to access or use existing prevention options.

‘This is why it remains a priority that we design and evaluate novel vaccine approaches such as HIVconsvX.’

The researchers hope to be able to report results of the HIV-CORE 006 trial at the end of 2022.

Similar stories

Leedham Lab receives funding to improve bowel cancer treatments

The Leedham Lab at the Wellcome Centre for Human Genetics in the Nuffield Department of Medicine (NDM) has been awarded over £2m from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from Nuffield Department of Medicine's Jenner Institute has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

New study provides important insights into TB correlates of protection

Researchers from the Nuffield Department of Medicine’s Jenner Institute have today reported the findings from a study investigating whether previously identified correlates of protection associated with the risk of tuberculosis (TB) disease could also be associated with the risk of infection from the bacteria that causes TB.

Therapeutic HIV vaccine achieves encouraging results

A phase I/IIa clinical trial that the Nuffield Department of Medicine's Jenner Institute collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.

Prof James Naismith elected as Academy of Medical Sciences' Vice President

Established in 1998, the Academy of Medical Sciences is one of the four UK National Academies, coordinating scholarly research activities and standards in the UK.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the two NIHR Biomedical Research Centres.